Y Intercept Hong Kong Ltd Takes $1.06 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 137,402 shares of the biotechnology company’s stock, valued at approximately $1,062,000. Y Intercept Hong Kong Ltd owned about 0.28% of REGENXBIO as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. FMR LLC grew its holdings in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares during the period. GAMMA Investing LLC grew its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares in the last quarter. Erste Asset Management GmbH acquired a new position in REGENXBIO in the third quarter valued at approximately $140,000. Finally, Intech Investment Management LLC bought a new position in shares of REGENXBIO during the 3rd quarter worth approximately $161,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Down 0.7 %

Shares of NASDAQ:RGNX opened at $6.67 on Thursday. The business’s 50 day moving average is $7.61 and its 200 day moving average is $9.50. REGENXBIO Inc. has a 12-month low of $6.44 and a 12-month high of $28.80. The stock has a market cap of $330.47 million, a price-to-earnings ratio of -1.33 and a beta of 1.29.

Analyst Ratings Changes

RGNX has been the subject of several research analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a research report on Wednesday, January 15th. Finally, Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and a consensus price target of $33.45.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.